ADGI ADAGIO THERAPEUTICS INC

Adagio Therapeutics to Participate in Upcoming Investor Conferences

Adagio Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases, today announced participation in the following upcoming investor conferences:

  • Morgan Stanley 20th Annual Global Healthcare Conference: Management will participate in a fireside chat on Monday, September 12, 2022, at 2:50 p.m. ET.



  • H.C. Wainwright 24th Annual Global Investment Conference: Management will participate in 1 on 1 meetings on Tuesday, September 13, 2022.

A live webcast of the fireside chat will be available in the investor section of the company's website at investors.adagiotx.com and will be archived for 90 days following the presentations.

About Adagio Therapeutics

Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases. The company is developing its lead product candidate, adintrevimab, for the prevention and treatment of COVID-19, the disease caused by the virus SARS-CoV-2 and its variants. The company is advancing proprietary antibodies targeting distinct sites with activity against all SARS-CoV-2 variants of concern to date and plans to take a combination of these antibodies into clinical trials in the first quarter of 2023. Beyond COVID-19, Adagio is leveraging its antibody discovery and development capabilities that have enabled expedited advancement of adintrevimab into clinical trials to develop therapeutic or preventative options for other infectious diseases, such as additional coronaviruses and influenza. Adintrevimab is an investigational monoclonal antibody that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established. For more information, please visit

Contacts

Media Contact:

Tony Berry, Evoke Canale

774-317-0422

Investor Contact:

Chris Brinzey, ICR Westwicke

339-970-2843



EN
06/09/2022

Underlying

ADGIADAGIO THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ADAGIO THERAPEUTICS INC

 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

New Publication Demonstrates Variant-Agnostic Correlate of Protection ...

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies “A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of Monoclonal Antibodies for Prevention of COVID-19” was published in Infectious Diseases and Therapy This peer-reviewed analysis describes the relationship between anti-COVID monoclonal antibody (mAb) levels in patient serum and demonstrated clinical protection from multipl...

February 24, 2026 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evalua...

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration LIBERTY is part of the Company’s broader REVOLUTION clinical program designed to elaborate the profile of monoclonal antibody-mediated prophylaxis from COVID-19 and the potential medical benefits to vulnerable AmericansThe LIBERTY clinical trial will evaluate comparative safety and immunology of VYD2311 versus mRNA COVID vaccine, as well as explore the safety and immunology o...

February 3, 2026 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Announces Partnership with World Champion Skier Lindsey Vonn t...

Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention The educational campaign will focus on teaching the American public about antibodies and preventing infectious diseaseThe collaboration will advance public understanding of antibodies as a centerpiece of modern wellness strategiesMedia campaign planned to launch in spring 2026 following Ms. Vonn’s closely watched and inspiring comeback season NEW HAVEN, Conn., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced a partnership with renown...

January 22, 2026 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD23...

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injuryParticipants to include people with Long COVID who demonstrate evidence of chronic infection or antigen persistence in a variety of tissues, and COVID vaccine-injured people including those who have demonstrated persistence of vaccine-delivered spike proteinDesign includ...

January 20, 2026 1 EN
 PRESS RELEASE
Free
ADGI ADAGIO THERAPEU...

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Bus...

Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarterPreliminary ending 2025 cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in D...

January 8, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch